Table 2 Trafficking, drug intracellular targets and bystander effects of ADCs that have received FDA approval or are enrolled in Phases II or III clinical trial
Name | Antigen | Receptor mediated endocytosis | Autophagy | Bystander effect | Target (drug) | Indication (stage) | |||
|---|---|---|---|---|---|---|---|---|---|
CCV | RE | EE | LE-Lys | ||||||
SGN35 Brentuxumab Vedotin | CD30 | + | na | na | + | na | + | Tubulin (MMAE) | ALCL and HK (FDA approved 2011) |
T-DM1 Trastuzumab Emtensine | HER2 | + | + | na | – | + | – | Tubulin (DM1) | HER2+ metastatic breast cancer (FDA approved 2013) |
SGN33 | CD33 | na | na | na | + | na | na | DNA (PBD) | |
IMGN779 | CD33 | na | na | na | na | na | + | DNA (IDB)) | |
ROVA-T | DLL3 | na | na | na | + | na | na | DNA (PBD) | |
CDX-011* Glemtumumab Vedotin | GPNMB | na | na | – | – | + | na | Tubulin (MMAE) | Melanoma, osteocarcinoma (Phase II) |
RG7596 Polatuzumab Vedotin | CD79b | na | na | na | + | na | na | Tubulin (MMAE) | NHL (Phase II) |
SGN-CD19A* Denintuzumab mafodotin | CD19 | + | na | na | + | na | na | Tubulin (MMAF) | NHL (Phase II) |
PSMA ADC* | PSMA | + | + | na | na | na | na | Tubulin (MMAE) | Prostate cancer (Phase II) |
IMGN853 Mirvetuximab soravtansine | FOLR1 | na | na | + | na | na | + | Tubulin (DM4) | Ovarian cancer (Phase III) |
SAR3419 Coltuximab ravtansine | CD19 | na | na | + | na | na | – | Tubulin (DM4) | Diffuse Large B cell lymphoma (Phase II) |
IMGN529 Naratuximab emtansine | CD37 | na | na | na | na | na | na | Tubulin (DM1) | NHL (Phase II) |
BT-062 Indatuximab ravtansine | CD138 | na | na | na | na | na | + | Tubulin (DM4) | Multiple myeloma (Phase II) |
Bay 94–9343 Anetumab ravtansine | Mesothelin | na | na | na | + | na | + | Tubulin (DM4) | Mesothelin expressing tumors (phase II) |
SAR408701 | CEACAM5 | na | na | na | na | na | na | Tubulin (DM4) | Solid tumors (Phase II) |
SAR428926 | LAMP1 | na | na | na | na | na | na | Tubulin (DM4) | Solid tumors (Phase II) |